<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044742</url>
  </required_header>
  <id_info>
    <org_study_id>STI-RTX-3001</org_study_id>
    <nct_id>NCT04044742</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee</brief_title>
  <official_title>A Phase 3 Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of intra-articular injection of resiniferatoxin&#xD;
      in patients with moderate to severe knee pain due to osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to evaluate the analgesic efficacy and safety of resiniferatoxin administered&#xD;
      intra-articularly to subjects with moderate to severe knee pain due to osteoarthritis (OA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    To be replaced by a different protocol&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The treatment assigned to each subject is blinded to the subject, investigators, and sponsor study team.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in index knee pain with walking</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Change in the weekly mean of Average Daily Pain (ADP) scores in the index knee, using the 10-point Numerical Pain Rating Scale (NPRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) change in average pain in the index knee</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>AUC calculated on change in the average pain in the index knee over the previous 24 hours, using the NPRS (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in index knee pain with walking</measure>
    <time_frame>Baseline through Week 26</time_frame>
    <description>Change in the weekly mean of ADP scores in the index knee, using the NPRS (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC change in average pain in the index knee</measure>
    <time_frame>Baseline through Week 26</time_frame>
    <description>AUC calculated on change in the average pain in the index knee over the previous 24 hours, using the NPRS (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of effect of a single injection in the index knee</measure>
    <time_frame>Baseline through return to Baseline</time_frame>
    <description>Time to return to baseline pain score, based on weekly average NPRS (0-10) scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in index knee pain, stiffness, and physical function</measure>
    <time_frame>Baseline through Week 12, Week 26, and Week 52</time_frame>
    <description>Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average pain in the index knee</measure>
    <time_frame>Baseline through Week 12, Week 26, and Week 52</time_frame>
    <description>Change in the WOMAC A pain subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average stiffness in the index knee</measure>
    <time_frame>Baseline through Week 12, Week 26, and Week 52</time_frame>
    <description>Change in the WOMAC B function subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the average function in the index knee</measure>
    <time_frame>Baseline through Week 12, Week 26, and Week 52</time_frame>
    <description>Change in the WOMAC C stiffness subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in index knee pain with walking</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Change in the weekly mean of ADP scores in the index knee, using the NPRS (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC change in average pain in the index knee</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>AUC calculated on change in the average pain in the index knee over the previous 24 hours, using the NPRS (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (QOL) - SF-36 Health Survey</measure>
    <time_frame>Baseline through Week 12, Week 26, and Week 52</time_frame>
    <description>Change in QOL as measured by the SF-36 Health Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of sleep</measure>
    <time_frame>Baseline through Week 12, Week 26, and Week 52</time_frame>
    <description>Change in quality of sleep as measured by the MOS Sleep Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>At Week 12, Week 26, and Week 52</time_frame>
    <description>Rating of change in index knee pain using the PGIC scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QOL - EQ-5D-5L</measure>
    <time_frame>Baseline through Week 12, Week 26, and Week 52</time_frame>
    <description>Change in QOL as measured by the EQ-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Knee Pain Chronic</condition>
  <arm_group>
    <arm_group_label>Resiniferatoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5 ug of Resiniferatoxin in 5 mL volume is administered as a one-time dose, intra-articularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo formulation in 5 mL volume administered intra-articularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resiniferatoxin</intervention_name>
    <description>Receiving Resiniferatoxin injection</description>
    <arm_group_label>Resiniferatoxin</arm_group_label>
    <other_name>RTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Receiving Placebo injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Diluent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 35 to 85 years of age (inclusive).&#xD;
&#xD;
          -  Diagnosis of moderate to severe pain in the index knee due to OA.&#xD;
&#xD;
          -  Pain in the non-index knee is less than pain in the index knee.&#xD;
&#xD;
          -  Body mass index ≤40 kg/m².&#xD;
&#xD;
          -  Experienced treatment failure with at least 2 prior categories of therapies.&#xD;
&#xD;
          -  Able to understand and complete study-related forms and communicate with the&#xD;
             Investigator and/or site staff.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of a serious coagulopathy or hemostasis problem, such as inherited&#xD;
             bleeding disorders or thrombocytopenia.&#xD;
&#xD;
          -  History of or current condition of poorly controlled hypertension, QTc prolongation,&#xD;
             history of risk factors for Torsades de Pointes, or family history of long QT&#xD;
             syndrome; or is using concomitant medications that prolong the QT interval.&#xD;
&#xD;
          -  Received index knee injections with corticosteroids within 30 days, or hyaluronic acid&#xD;
             within 3 months, or platelet-rich plasma within 6 months prior to the injection day.&#xD;
&#xD;
          -  Pre-existing osteonecrosis, subchondral insufficiency fracture, severe bone on bone&#xD;
             OA, or knee pain attributable to disease other than OA.&#xD;
&#xD;
          -  Instability or misalignment in the index knee.&#xD;
&#xD;
          -  Concurrent use of opioids or indications other than knee pain.&#xD;
&#xD;
          -  History within the past 2 years of substance abuse, including alcohol.&#xD;
&#xD;
          -  Allergy or hypersensitivity to chili peppers, capsaicin, resiniferatoxin,&#xD;
             acetaminophen, tramadol, or radiographic contrast agents.&#xD;
&#xD;
          -  Female participants who are pregnant, planning on becoming pregnant, or currently&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Any medical condition or comorbidities that, in the Investigator's opinion, could&#xD;
             adversely impact study participation or safety, conduct of the study, or interfere&#xD;
             with pain assessments.&#xD;
&#xD;
          -  Sensory peripheral neuropathy that is of moderate severity or higher.&#xD;
&#xD;
          -  Arterial or venous thrombi (including stroke), myocardial infarction, hospital&#xD;
             admission for unstable angina, cardiac angioplasty, or stenting within the past 12&#xD;
             months.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome-related&#xD;
             illness, acute or history of chronic hepatitis B or hepatitis C. Participants with&#xD;
             these viral infections who are receiving or have received antiviral treatment and have&#xD;
             a viral load that is undetectable are eligible.&#xD;
&#xD;
          -  Concurrent medical or arthritic conditions that could interfere with the evaluation of&#xD;
             the index knee joint including chondromalacia patellae, metabolic diseases,&#xD;
             gout/pseudogout, hemochromatosis, acromegaly, fibromyalgia, rheumatoid arthritis, or&#xD;
             other inflammatory arthropathies affecting the knee joint.&#xD;
&#xD;
          -  Undergone arthroscopic surgery of the index knee within 6 months of the injection day,&#xD;
             or open surgery to the index knee within 24 months of the injection day.&#xD;
&#xD;
          -  Undergone replacement surgery of the index knee.&#xD;
&#xD;
          -  Presence of surgical hardware or other foreign bodies in the index knee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Luchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

